The attainment of this rating strongly reflects the merits of business collaboration of the strategic alliance with Roche. Through this alliance, Chugai can efficiently and exclusively market innovative products in-licensed from Roche in Japan, and this stable revenue base enables Chugai to specialize and invest in highly innovative proprietary technologies and drug discovery. In addition, by out-licensing Chugai originated products to Roche, Chugai can expand into the global market that will become a revenue base that drives growth. Chugai also has a strong financial base and can maintain high profitability in the medium term. These conditions have led to a raise in Chugai’s rating to “AA.” Chugai will continue working to improve Chugai’s profitability and financial base.

For a detailed explanation of the rating, please refer to the R&I announcement.
Rating and Investment Information, Inc. (R&I) website